US 2022/0023388 A1Published application

Fusion proteins with extended serum half life

AssigneesThe National Institute for Biotechnology In the Negev Ltd., B. G. Negev Technologies and Applications Ltd., At Ben-Gurion University

InventorsAri-Angel PORGADOR, David BEN-MENAHEM, Roee ATLAS

Life of this patent

Estimating the term…

Abstract

Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.

Claims18

Dependent claims

A peptide comprising 20 to 50 amino acid residues derived from amino acids 130 to 199 of SEQ ID NO:

Dependencies are inferred from the claim text.

Facts

Application: 17/498,262Filed 11 Oct 2021
Priority: 11 Jul 2016
Published: 27 Jan 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61K 38/19
From animals; from humans: cytokines; Lymphokines; Interferons
A61K 38/18
From animals; from humans: growth factors; Growth regulators
A61K 47/642
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is…: the…
C07K 14/55
Interleukins [IL]: il-2

Family

Application62/360,524Us provisional application · filed 11 Jul 2016
Application62/421,400Us provisional application · filed 14 Nov 2016
Application16/316,410Continuation · filed 9 Jan 2019
Application17/498,262Continuation
US 11,141,463 B2Related patent
US 11,911,443 B2Related patent
US 2019/0255150 A1Published application
US 2022/0023388 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results